Positron Emission Tomography (PET): Principles, Uses, and Limitations

How PET works

A PET study begins with administration of a tracer that emits positrons as it decays. When a positron encounters an electron in tissue, the two annihilate and produce a pair of gamma photons that travel in nearly opposite directions. A ring of detectors surrounding the patient records coincident photon events; software reconstructs these events into a three‑dimensional image showing where annihilations — and thus tracer concentration — occurred. Modern systems use scintillation crystals and coincidence timing to improve sensitivity and spatial resolution, and images are often corrected for attenuation and scatter to improve accuracy.

Tracers and production

Tracers vary according to the physiological process of interest. The most widely used tracer in clinical PET is a glucose analogue labelled with the radioisotope fluorine‑18, which highlights regions of high glucose metabolism such as many tumors or active brain areas. Other tracers target neurotransmitter receptors, amyloid plaques in neurodegenerative disease, or myocardial blood flow. Because the radioactive isotopes used decay quickly, tracers must be produced close to the imaging site, typically in a cyclotron and synthesized in a radiochemistry laboratory. That short radioactive half-life and the need for specialized production facilities affect logistics and cost. The administered substance itself is often referred to as a tracer in clinical reports and research papers.

Clinical and research applications

• Oncology: staging, detecting recurrence, and monitoring response to therapy.
• Neurology: evaluating epilepsy, dementia, movement disorders, and brain metabolism.
• Cardiology: assessing myocardial viability and perfusion.
• Drug development and basic research: measuring pharmacokinetics, receptor occupancy, and molecular pathways.

Advantages, limitations and notable facts

PET provides sensitive, quantitative information about function that complements anatomical imaging. Combined systems such as PET/CT and PET/MRI fuse metabolic data with high‑resolution anatomy, improving lesion localization and diagnostic confidence. Limitations include limited spatial resolution compared with structural imaging, exposure to ionizing radiation, high equipment and operational costs, and dependency on short‑lived tracers that require nearby production. Despite these constraints, PET remains a cornerstone of precision diagnosis, treatment planning, and biomedical research because it can reveal disease activity at a molecular level before structural changes appear.

Practical considerations

Preparation and interpretation of PET studies involve multidisciplinary teams: nuclear medicine physicians, radiochemists, technologists, medical physicists and referring clinicians. Patient preparation often includes fasting or other protocol‑specific instructions to optimize tracer distribution. As tracer chemistry and detector technology evolve, PET continues to expand its role across clinical specialties and translational research.